Pulmonary Hypertension Roundtable: Perspectives on PHA's 10th International PH Conference

2012 ◽  
Vol 11 (3) ◽  
pp. 135-140
Keyword(s):  
Pulmonary Hypertension ◽  
Medical Center ◽  
Assistant Professor ◽  
Associate Professor ◽  
Medical Director ◽  
Pulmonary Vascular Disease ◽  
University Of Utah ◽  
University Of Colorado ◽  
Assistant Director ◽  
Vanderbilt University

As a way to integrate the presentations at PHA's June scientific sessions with clinical practice, Guest Editor Karen Fagan, MD, convened a group of attendees to discuss their experience in Orlando. The discussants included Todd Bull, MD, Associate Professor, Medical Director, Anschutz Intensive Care Unit, University of Colorado, Aurora, Colorado; Anna Hemnes, MD, Assistant Director, Center for Adult Pulmonary Vascular Disease, Vanderbilt University, Nashville, Tennessee; C. Gregory Elliott, MD, Professor of Medicine, University of Utah and Medical Director, Pulmonary Hypertension Center, Intermountain Medical Center, Murray, Utah; Vinicio A. de Jesus Perez, MD, Assistant Professor in Medicine and Staff Physician, Wall Center Adult PH Clinic, Stanford University Medical Center, Palo Alto, California; and Paul B. Yu, MD, PhD, Brigham and Women's Hospital, Boston, Massachusetts.

Pulmonary Hypertension Roundtable: The Challenging Spectrum of PH in Liver and Kidney Transplantation Patients

2013 ◽  
Vol 12 (2) ◽  
pp. 88-93
Keyword(s):  
Pulmonary Hypertension ◽  
Kidney Transplantation ◽  
Mayo Clinic ◽  
Medical Center ◽  
Assistant Professor ◽  
Pulmonary Vascular Disease ◽  
Clinical Expertise ◽  
University Of Pittsburgh ◽  
Liver And Kidney ◽  
Assistant Director

On August 16, 2013, a group of physicians with clinical expertise related to management of pulmonary hypertension (PH) patients who are undergoing evaluation for or having liver or kidney transplantation was convened by telephone to discuss this challenging topic. These complex patients represent a spectrum of clinical types of PH and require complete evaluations utilizing a team-oriented and multidisciplinary approach to ensure appropriate treatment and safe transplantation. Facilitated by the guest editors of this issue, Charles Burger, MD, and Paul Forfia, MD, discussants included Michael Krowka, MD, Professor of Medicine, Pulmonary Division, Mayo Clinic, Rochester, Minnesota; José Diaz-Gómez, MD, Medical Director-ICU, Departments of Anesthesiology and Critical Care, Mayo Clinic, Jacksonville, Florida; Anna Hemnes, MD, Assistant Professor, Assistant Director, Pulmonary Vascular Disease Program Vanderbilt University Medical Center, Nashville, Tennessee; and Michael Mathier, MD, Assistant Professor of Medicine, Director, Pulmonary Hypertension Program, and Associate Director, Cardiovascular Fellowship Program of the University of Pittsburgh Medical Center.

Protocols in Heart and Lung Transplantation: An Essential Guide to Preoperative Assessment and Timing to Improve Outcomes

2004 ◽  
Vol 3 (1) ◽  
pp. 20-25
Author(s):  
Victor Tapson ◽  
Robert Frantz ◽  
John Conte
Keyword(s):  
North Carolina ◽  
Pulmonary Hypertension ◽  
Critical Care ◽  
Lung Transplantation ◽  
Medical Center ◽  
Preoperative Assessment ◽  
Assistant Professor ◽  
Associate Professor ◽  
Johns Hopkins University ◽  
Duke University

This discussion was moderated by Victor Tapson, MD, Editor-in-Chief of Advances in Pulmonary Hypertension and Associate Professor, Division of Pulmonary and Critical Care Medicine, Duke University Medical Center, Durham, North Carolina. The participants included Robert Frantz, MD, Assistant Professor of Medicine, Cardiovascular Division, Mayo Clinic, Rochester, Minnesota; and John Conte, MD, Associate Professor of Surgery and Director of Heart and Lung Transplantation, Johns Hopkins University, Baltimore, MD.

scholarly journals Imatinib: A Perspective on Its Potential for PAH Patients

2012 ◽  
Vol 11 (1) ◽  
pp. 41-46
Author(s):  
R. James White ◽  
Mardi Gomberg-Maitland ◽  
Jeremy Feldman ◽  
Ioana Preston ◽  
Steve Mathai
Keyword(s):  
Pulmonary Hypertension ◽  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Medical Center ◽  
Assistant Professor ◽  
Associate Professor ◽  
Phase Iii ◽  
Recent Phase ◽  
Hemodynamic Impairment ◽  
Pulmonary Arterial

We invited 4 experts to a telephone roundtable facilitated by guest editor Jim White, MD, PhD, on April 13, 2012, to discuss the results of the recent Phase III trial, the Imatinib in Pulmonary Arterial Hypertension (IMPRES) trial (NCT00902174). Investigators enrolled patients with pulmonary arterial hypertension with severe hemodynamic impairment at catheterization despite treatment with 2 background therapies. Patients were randomized to placebo or 200 mg imatinib twice daily for 6 months of therapy to assess efficacy. Participating in the discussion were Mardi Gomberg-Maitland, MD, MSc, Associate Professor of Medicine and Director, Pulmonary Hypertension Center, University of Chicago; Iona Preston, MD, Co-director, Pulmonary Hypertension Center, Tufts University Medical Center, Boston; Jeremy Feldman, MD, Director, Pulmonary Hypertension Program, Medical Director of Research, Arizona Pulmonary Specialists, Phoenix; Stephen Mathai, MD, MHS, Assistant Professor of Medicine, The Johns Hopkins School of Medicine, Baltimore.

scholarly journals Meeting the Challenge of Surgery and Pulmonary Hypertension: How to Manage the “Hemodynamic Environment” to Optimize Outcomes

2007 ◽  
Vol 6 (2) ◽  
pp. 92-95
Author(s):  
Richard Channick ◽  
Kenneth R. McCurry ◽  
Ronald Pearl ◽  
Stuart Rich
Keyword(s):  
Pulmonary Hypertension ◽  
Critical Care ◽  
Lung Transplantation ◽  
San Diego ◽  
Medical Center ◽  
Assistant Professor ◽  
Associate Professor ◽  
University Of California ◽  
University Of Pittsburgh ◽  
School Of Medicine

This discussion was moderated by Richard Chan-nick, MD, Associate Professor of Medicine, Pulmonary and Critical Care Division, University of California, San Diego Medical Center, San Diego, California. Panel members included Kenneth R. McCurry, MD, Assistant Professor of Surgery, Division of Cardiothoracic Surgery, Director, Lung and Heart-Lung Transplantation Programs, University of Pittsburgh Department of Surgery, Pittsburgh, Pennsylvania; Ronald Pearl, MD, PhD, Professor and Chair, Anesthesia Department, Stanford University School of Medicine, Stanford, California; and Stuart Rich, MD, Professor of Medicine, Section of Cardiology, Center for Pulmonary Hypertension, University of Chicago, Chicago, Illinois.

Sickle Cell Disease and Pulmonary Hypertension: Addressing the Mixed Pathology and Special Considerations in Diagnosis and Treatment

2007 ◽  
Vol 6 (1) ◽  
pp. 39-44
Author(s):  
Harrison W. Farber ◽  
Mark Gladwin ◽  
Evelyn M. Horn ◽  
Myung H. Park
Keyword(s):  
New York ◽  
Pulmonary Hypertension ◽  
Vascular Disease ◽  
Clinical Medicine ◽  
Medical Center ◽  
Associate Professor ◽  
Pulmonary Vascular Disease ◽  
Vascular Medicine ◽  
Blood Institute ◽  
School Of Medicine

This discussion was moderated by Evelyn M. Horn, MD, Associate Professor of Clinical Medicine and Director, Pulmonary Vascular Disease, Center for Advanced Cardiac Care, Columbia University Medical Center, New York, New York. Panel members included Harrison W. Farber, MD, Director, Pulmonary Hypertension Center, Boston Medical Center, Boston University School of Medicine; Mark Gladwin, MD, Chief, Vascular Medicine Branch, National Heart, Lung, and Blood Institute, Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD; Myung H. Park, MD, Director, Pulmonary Vascular Disease Program, University of Maryland School of Medicine.

scholarly journals PH Roundtable: Pulmonary Hypertension Roundtable: Clinical Experiences With Drug- and Toxin-Related PH

2018 ◽  
Vol 17 (2) ◽  
pp. 80-85
Keyword(s):  
Pulmonary Hypertension ◽  
Medical Center ◽  
Assistant Professor ◽  
Associate Professor ◽  
Texas Southwestern Medical ◽  
Clinical Experiences ◽  
University Of Texas ◽  
School Of Medicine ◽  
Hypertension Clinic ◽  
The University

Sonja Bartolome, MD, pulmonary hypertension specialist and Director of Liver Transplant Critical Care at University of Texas Southwestern Medical Center, Dallas, facilitated a comprehensive discussion among 4 additional clinical experts regarding their experiences with the broad-ranging issues related to treating patients with drug- and toxin-related pulmonary hypertension. Joining the call on May 3, 2018, were Vinicio de Jesus Perez, MD, Assistant Professor of Medicine and staff physician and Roham Zamanian, MD, Associate Professor of Medicine and Medical Director, from the Pulmonary Hypertension Clinic at Stanford University School of Medicine; Kelly Chin, MD, Director of the Pulmonary Hypertension Center at University of Texas Southwestern Medical Center; and Konstadina Darsaklis, MD, Assistant Professor at the University of Connecticut, and cardiologist at Hartford Hospital where she started the pulmonary hypertension clinic.

scholarly journals Expanded Use of PAH Medications

2008 ◽  
Vol 7 (1) ◽  
pp. 249-254
Author(s):  
Karen A. Fagan ◽  
Kamal K. Mubarak ◽  
Zeenat Safdar ◽  
Aaron Waxman ◽  
Roham T. Zamanian
Keyword(s):  
Pulmonary Hypertension ◽  
Critical Care ◽  
Vascular Disease ◽  
Massachusetts General Hospital ◽  
Assistant Professor ◽  
Associate Professor ◽  
Pulmonary Vascular Disease ◽  
Pulmonary Medicine ◽  
State University ◽  
Wayne State University

This discussion was moderated by Karen A. Fagan, MD, Professor and Director, Division of Pulmonary Medicine, University of South Alabama College of Medicine, Mobile, Alabama. Panel members included Kamal K. Mubarak, MD, Assistant Professor of Medicine, Director, Pulmonary Hypertension Clinic, Wayne State University, Detroit, Michigan; Zeenat Safdar, MD, Assistant Professor of Medicine, Department of Medicine, Section of Pulmonary, Critical Care, and Sleep Medicine, Baylor College of Medicine, Houston, Texas; Aaron Waxman, MD, PhD, Associate Professor of Medicine, Harvard Medical School, Director, Pulmonary Vascular Disease Program and Pulmonary Critical Care Unit, Massachusetts General Hospital, Boston, Massachusetts; and Roham T. Zamanian, MD, Assistant Professor of Medicine, Director, Adult Pulmonary Hypertension Clinical Service, Vera Moulton Wall Center for Pulmonary Vascular Disease, Stanford University School of Medicine, Stanford, California.

scholarly journals • Recapping Highlights from the 2006 PHA Scientific Sessions• Reviewing New Perspectives on Inflammation, Genetics, and Imaging• Redefining Exercise-Induced PH• Future Considerations in Translational Research

2006 ◽  
Vol 5 (3) ◽  
pp. 34-39
Author(s):  
Karen A. Fagan ◽  
David B. Badesch ◽  
C. Gregory Elliott ◽  
Robert P. Frantz
Keyword(s):  
Mayo Clinic ◽  
Salt Lake ◽  
Salt Lake City ◽  
Assistant Professor ◽  
Health Sciences ◽  
Associate Professor ◽  
University Of Utah ◽  
University Of Colorado ◽  
Colorado Health ◽  
Lake City

This discussion was moderated by Karen A. Fagan, MD, Associate Professor of Medicine, University of Colorado Health Sciences Center, Denver, Colorado. Panel members included David B. Badesch, MD, Professor of Medicine, Divisions of Pulmonary Sciences & Critical Care Medicine, and Cardiology Clinical Director, Pulmonary Hypertension Center, University of Colorado Health Sciences Center, Denver, Colorado; C. Gregory Elliott, MD, Professor of Medicine, University of Utah School of Medicine, Pulmonary Division, LDS Hospital, Salt Lake City, Utah; and Robert P. Frantz, MD, Assistant Professor of Medicine, Mayo Clinic College of Medicine, Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minnesota.

scholarly journals Pulmonary Hypertension Roundtable

2005 ◽  
Vol 4 (2) ◽  
pp. 24-29
Author(s):  
Richard Channick ◽  
Hap Farber ◽  
Nicholas Hill ◽  
Robert Schilz
Keyword(s):  
Pulmonary Hypertension ◽  
Critical Care ◽  
New England ◽  
San Diego ◽  
Medical Center ◽  
Assistant Professor ◽  
Associate Professor ◽  
University Of California ◽  
Boston University ◽  
England Medical

This discussion was moderated by Richard Channick, MD, Associate Professor of Medicine, Pulmonary and Critical Care Division, University of California, San Diego Medical Center, San Diego, California. The physicians participating included Hap Farber, MD, Director, Pulmonary Hypertension Center, Boston University Medical Center, Boston, Massachusetts; Nicholas Hill, MD, Chief, Pulmonary, Critical Care and Sleep Division, Tufts-New England Medical Center, Boston, Massachusetts; and Robert Schilz, PhD, DO, Director of Lung Transplantation and Advanced Lung Disease, and Assistant Professor of Medicine, Case Western Reserve University, Cleveland, Ohio.

PH and Left Heart Disease: Defining the Clinical Dilemma

2011 ◽  
Vol 10 (1) ◽  
pp. 49-56
Author(s):  
Myung H. Park ◽  
Rene Alvarez ◽  
Teresa De Marco ◽  
Ivan Robbins ◽  
Marc Semigran
Keyword(s):  
Heart Failure ◽  
Pulmonary Hypertension ◽  
San Francisco ◽  
Medical Center ◽  
Associate Professor ◽  
Outreach Program ◽  
Pulmonary Vascular Disease ◽  
Cardiac Transplant ◽  
Transplant Program ◽  
School Of Medicine

A panel of experts convened by telephone on April 20, 2011 to discuss their experiences and recommendations regarding diagnosis and management of patients with Group 2 PH. The conversation was facilitated by Myung Park, MD, Associate Professor of Medicine and Director, Pulmonary Vascular Disease Program, Division of Cardiology at University of Maryland School of Medicine and guest editor of this issue. The participants were Rene Alvarez, MD, Associate Professor of Medicine and Director, Advanced Heart Failure/Pulmonary Hypertension Outreach Program, University of Pittsburgh School of Medicine; Teresa De Marco, MD, Professor of Medicine, Director, Heart Failure and Pulmonary Hypertension Program and Director, Heart Transplantation, University of California San Francisco Medical Center; Marc Semigran, MD, Medical Director of the Heart Failure and Cardiac Transplant Program at the Massachusetts General Hospital Center and Associate Professor of Medicine at Harvard Medical School; and Ivan Robbins, MD, Assistant Professor of Medicine and Director, Lung Transplant Program, Vanderbilt University Medical Center.

Sign in / Sign up

Export Citation Format

Share Document